Alkermes (NASDAQ:ALKS) Stock Price Target Raised at HC Wainwright

Alkermes (NASDAQ:ALKS) had its price objective upped by HC Wainwright from $43.00 to $50.00 in a report issued on Wednesday morning, MarketBeat reports. They currently have a neutral rating on the stock.

Several other analysts have also commented on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Alkermes in a research report on Friday, August 7th. The Goldman Sachs Group started coverage on Alkermes in a research report on Thursday, September 24th. They set a “neutral” rating and a $50.00 price objective for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $63.00 target price (up from $45.00) on shares of Alkermes in a research note on Monday, July 20th. Mizuho upgraded Alkermes to a “strong-buy” rating in a report on Wednesday, September 16th. Finally, Piper Sandler reissued an “overweight” rating and set a $65.00 price target (up from $43.00) on shares of Alkermes in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $55.06.

Alkermes Price Performance

Shares of NASDAQ ALKS opened at $45.89 on Wednesday. The stock has a market cap of $7.70 billion, a price-to-earnings ratio of 1,523.00 and a beta of 0.32. Alkermes has a 52 week low of $27.00 and a 52 week high of $55.67. The company’s 50-day moving average price is $43.86 and its 200 day moving average price is $40.66. The company has a current ratio of 2.47, a quick ratio of 1.85 and a debt-to-equity ratio of 0.79.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Tuesday, November 3rd. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.17. The firm had revenue of $480.13 million during the quarter, compared to the consensus estimate of $463.48 million. Alkermes had a negative net margin of 0.02% and a positive return on equity of 0.40%. The firm’s revenue for the quarter was up 21.8% on a year-over-year basis. During the same period last year, the firm posted $0.49 EPS. As a group, research analysts forecast that Alkermes will post -0.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Alkermes

In other news, EVP David Gaffin sold 2,035 shares of Alkermes stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $46.17, for a total transaction of $93,955.95. Following the completion of the sale, the executive vice president directly owned 219,353 shares in the company, valued at $10,127,528.01. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christian Nichols sold 7,576 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $49.23, for a total transaction of $372,966.48. Following the completion of the transaction, the senior vice president directly owned 102,193 shares of the company’s stock, valued at approximately $5,030,961.39. This represents a 6.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 22,679 shares of company stock worth $1,070,940. Corporate insiders own 4.59% of the company’s stock.

Hedge Funds Weigh In On Alkermes

Several institutional investors and hedge funds have recently modified their holdings of ALKS. M&G PLC purchased a new position in shares of Alkermes during the 3rd quarter worth $14,368,000. Allspring Global Investments Holdings LLC grew its position in shares of Alkermes by 236.1% in the third quarter. Allspring Global Investments Holdings LLC now owns 85,682 shares of the company’s stock valued at $3,474,000 after purchasing an additional 60,188 shares during the period. Pictet Asset Management Holding SA grew its position in shares of Alkermes by 20.4% in the third quarter. Pictet Asset Management Holding SA now owns 1,009,318 shares of the company’s stock valued at $41,012,000 after purchasing an additional 171,292 shares during the period. CenterBook Partners LP grew its position in shares of Alkermes by 88.3% in the third quarter. CenterBook Partners LP now owns 13,938 shares of the company’s stock valued at $565,000 after purchasing an additional 6,535 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Alkermes in the third quarter valued at $347,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes News Summary

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Alkermes reported third-quarter EPS of $0.09, versus analysts’ expectation of a $0.08 loss, and revenue of $480.1 million, ahead of the $463.5 million consensus and up 21.8% year over year. Article: Alkermes Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Royal Bank of Canada raised its price target from $56 to $57 and maintained an outperform rating, signaling continued analyst confidence. Royal Bank of Canada ratings
• Positive Sentiment: The company reiterated its fourth-quarter proprietary net sales outlook of $400 million to $420 million and expects Phase III data for alixorexton around mid-2027, offering a defined pipeline milestone. Article: Alkermes reiterates sales outlook and Phase III timing
• Neutral Sentiment: HC Wainwright lifted its target from $43 to $50 but kept a neutral rating, reflecting a higher valuation estimate without a more bullish recommendation. HC Wainwright ratings
• Neutral Sentiment: EVP David Gaffin sold 2,035 shares, about 0.92% of his holdings. The transaction was made under a pre-arranged Rule 10b5-1 plan, making it less indicative of a fresh change in his outlook. Article: Insider share sale
• Negative Sentiment: Despite the beat, third-quarter profit was reported at $16 million and EPS fell from $0.49 a year earlier. A separate analysis also raised concerns that the shares may be overvalued following the ALKS 7290 trial launch. Article: Lower Q3 profit Article: Valuation concerns

Alkermes Company Profile

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.